Jan Dyer

When veterans receive emergency care at non-VA facilities, they can file for reimbursement of non-VA emergency care costs. If the claims are denied or rejected, non-VA facilities and providers can bill the veterans for some or all of the costs.

A stunning VA Office of Inspector General (OIG) report issued in August revealed that the VA had wrongfully rejected thousands of those emergency-care claims between April 1, 2017 and September 30, 2017. The OIG report said VA supervisors had pressured staff to quickly decide claims and even deny claims to maximize productivity. That culture of “speed over accuracy” led to 31% of claims being “inappropriately processed.”

Under regulations, when a claim is denied it is because there is no basis for payment, but a claim may also be rejected, meaning it cannot be decided until the claimant provides additional or corrected information. When the Claims Adjudication and Reimbursement Directorate (CAR) in the VA Office of Community Care (OCC) denies a claim, the claimant may have to pay out of pocket for emergency care.

The billed amount of inappropriately processed claims in those 5 months that were denied or rejected was “large in the aggregate,” the report said: an estimated $716 million, presenting potential undue financial risk to an estimated 60,800 veterans. The OIG estimated that about 17,400 veterans, with bills of at least $53.3 million, were negatively affected during the audit period. If corrective actions are not taken, the OIG estimates that the errors could result in $533 million in improper underpayments over 5 years.

The OIG audit was initiated after then Representative Tim Walz (D-MN) raised the concern in September 2017 about claims processors denying non-VA claims not only to meet production goals, but also to receive incentives such as high-performance ratings, bonuses, and telework privileges. The OIG audit also found that examiners who did not consistently meet the production numbers were not considered for overtime and had their telework privileges removed.

Other processing errors were also significant, the report says. For example, claimants did not receive complete and accurate information regarding why their claims were denied or rejected. Those errors created a risk that claimants could not effectively respond with information to get their claims approved.

The pressure to approve or deny claims quickly stemmed from a backlog of claims > 30 days old, which OCC and CAR leaders tried to reduce, the report says.

The OIG notes that since FY 2017 the OCC “experienced several leadership changes,” including 3 CAR directors. While the audit’s findings cannot be tied directly to those changes, the instability “provided the context in which problems were allowed to continue without remediation.”

In May, VHA officials reported to the audit team that they had implemented process improvements and initiatives that affect claims processing nationwide, and “the environment in which claims are processed.” Richard Stone, executive in charge of the VHA, submitted plans to comply with the IG’s 11 recommendations, which included tying incentives to all performance standards rather than just production quantity.

The US Court of Appeals for Veterans Claims recently ruled that the VA must reimburse veterans for emergency medical care at non-VA facilities—potentially between $1.8 billion and $6.5 billion in reimbursements for veterans who have filed or will file claims between 2016 and 2025. The court also struck down an internal VA regulation that blocked such payments. In 2015, the court had struck down a previous version of the internal regulation that refused coverage for an emergency claim when another form of insurance covered even a small part of the bill. The court said that regulation violated a 2010 federal law. In last month’s ruling, the court found the department had violated the same federal law with its revision of the reimbursement regulation, issued in 2018. The new rule, the panel said, created a new obstacle for veterans.

When veterans receive emergency care at non-VA facilities, they can file for reimbursement of non-VA emergency care costs. If the claims are denied or rejected, non-VA facilities and providers can bill the veterans for some or all of the costs.

A stunning VA Office of Inspector General (OIG) report issued in August revealed that the VA had wrongfully rejected thousands of those emergency-care claims between April 1, 2017 and September 30, 2017. The OIG report said VA supervisors had pressured staff to quickly decide claims and even deny claims to maximize productivity. That culture of “speed over accuracy” led to 31% of claims being “inappropriately processed.”

Under regulations, when a claim is denied it is because there is no basis for payment, but a claim may also be rejected, meaning it cannot be decided until the claimant provides additional or corrected information. When the Claims Adjudication and Reimbursement Directorate (CAR) in the VA Office of Community Care (OCC) denies a claim, the claimant may have to pay out of pocket for emergency care.

The billed amount of inappropriately processed claims in those 5 months that were denied or rejected was “large in the aggregate,” the report said: an estimated $716 million, presenting potential undue financial risk to an estimated 60,800 veterans. The OIG estimated that about 17,400 veterans, with bills of at least $53.3 million, were negatively affected during the audit period. If corrective actions are not taken, the OIG estimates that the errors could result in $533 million in improper underpayments over 5 years.

The OIG audit was initiated after then Representative Tim Walz (D-MN) raised the concern in September 2017 about claims processors denying non-VA claims not only to meet production goals, but also to receive incentives such as high-performance ratings, bonuses, and telework privileges. The OIG audit also found that examiners who did not consistently meet the production numbers were not considered for overtime and had their telework privileges removed.

Other processing errors were also significant, the report says. For example, claimants did not receive complete and accurate information regarding why their claims were denied or rejected. Those errors created a risk that claimants could not effectively respond with information to get their claims approved.

The pressure to approve or deny claims quickly stemmed from a backlog of claims > 30 days old, which OCC and CAR leaders tried to reduce, the report says.

The OIG notes that since FY 2017 the OCC “experienced several leadership changes,” including 3 CAR directors. While the audit’s findings cannot be tied directly to those changes, the instability “provided the context in which problems were allowed to continue without remediation.”

In May, VHA officials reported to the audit team that they had implemented process improvements and initiatives that affect claims processing nationwide, and “the environment in which claims are processed.” Richard Stone, executive in charge of the VHA, submitted plans to comply with the IG’s 11 recommendations, which included tying incentives to all performance standards rather than just production quantity.

The US Court of Appeals for Veterans Claims recently ruled that the VA must reimburse veterans for emergency medical care at non-VA facilities—potentially between $1.8 billion and $6.5 billion in reimbursements for veterans who have filed or will file claims between 2016 and 2025. The court also struck down an internal VA regulation that blocked such payments. In 2015, the court had struck down a previous version of the internal regulation that refused coverage for an emergency claim when another form of insurance covered even a small part of the bill. The court said that regulation violated a 2010 federal law. In last month’s ruling, the court found the department had violated the same federal law with its revision of the reimbursement regulation, issued in 2018. The new rule, the panel said, created a new obstacle for veterans.

When veterans receive emergency care at non-VA facilities, they can file for reimbursement of non-VA emergency care costs. If the claims are denied or rejected, non-VA facilities and providers can bill the veterans for some or all of the costs.

A stunning VA Office of Inspector General (OIG) report issued in August revealed that the VA had wrongfully rejected thousands of those emergency-care claims between April 1, 2017 and September 30, 2017. The OIG report said VA supervisors had pressured staff to quickly decide claims and even deny claims to maximize productivity. That culture of “speed over accuracy” led to 31% of claims being “inappropriately processed.”

Under regulations, when a claim is denied it is because there is no basis for payment, but a claim may also be rejected, meaning it cannot be decided until the claimant provides additional or corrected information. When the Claims Adjudication and Reimbursement Directorate (CAR) in the VA Office of Community Care (OCC) denies a claim, the claimant may have to pay out of pocket for emergency care.

The billed amount of inappropriately processed claims in those 5 months that were denied or rejected was “large in the aggregate,” the report said: an estimated $716 million, presenting potential undue financial risk to an estimated 60,800 veterans. The OIG estimated that about 17,400 veterans, with bills of at least $53.3 million, were negatively affected during the audit period. If corrective actions are not taken, the OIG estimates that the errors could result in $533 million in improper underpayments over 5 years.

The OIG audit was initiated after then Representative Tim Walz (D-MN) raised the concern in September 2017 about claims processors denying non-VA claims not only to meet production goals, but also to receive incentives such as high-performance ratings, bonuses, and telework privileges. The OIG audit also found that examiners who did not consistently meet the production numbers were not considered for overtime and had their telework privileges removed.

Other processing errors were also significant, the report says. For example, claimants did not receive complete and accurate information regarding why their claims were denied or rejected. Those errors created a risk that claimants could not effectively respond with information to get their claims approved.

The pressure to approve or deny claims quickly stemmed from a backlog of claims > 30 days old, which OCC and CAR leaders tried to reduce, the report says.

The OIG notes that since FY 2017 the OCC “experienced several leadership changes,” including 3 CAR directors. While the audit’s findings cannot be tied directly to those changes, the instability “provided the context in which problems were allowed to continue without remediation.”

In May, VHA officials reported to the audit team that they had implemented process improvements and initiatives that affect claims processing nationwide, and “the environment in which claims are processed.” Richard Stone, executive in charge of the VHA, submitted plans to comply with the IG’s 11 recommendations, which included tying incentives to all performance standards rather than just production quantity.

The US Court of Appeals for Veterans Claims recently ruled that the VA must reimburse veterans for emergency medical care at non-VA facilities—potentially between $1.8 billion and $6.5 billion in reimbursements for veterans who have filed or will file claims between 2016 and 2025. The court also struck down an internal VA regulation that blocked such payments. In 2015, the court had struck down a previous version of the internal regulation that refused coverage for an emergency claim when another form of insurance covered even a small part of the bill. The court said that regulation violated a 2010 federal law. In last month’s ruling, the court found the department had violated the same federal law with its revision of the reimbursement regulation, issued in 2018. The new rule, the panel said, created a new obstacle for veterans.

About 100,000 people in America have sickle cell disease. Of those, an estimated 27 people have undergone experimental gene therapy using conventional vectors—virus-based vehicles for delivering “therapeutic genes.” Now National Institutes of Health researchers have taken the vector idea and revved it up, bringing the possibility of curing sickle cell disease a bit closer.

With gene therapy, doctors add a normal copy of the β-globin gene to the patient’s hematopoietic stem cells, then reinfuse the modified stem cells into the patient to produce normal disc-shaped red blood cells. In animal studies, the new vector was up to 10 times more efficient at incorporating corrective genes into bone marrow stem cells with a carrying capacity of up to 6 times greater viral load than current vectors. The new vectors also can be produced in much higher amounts, saving time and lowering costs.

The researchers call it a “forward-oriented” vector because it changes the usual direction of how gene sequences in globin-containing vectors are read: from right to left. That backward orientation—globin-containing vectors are the only therapeutic vectors in clinical development that use it—the researchers say, “has remained unchallenged for decades despite its negative impacts on efficiency.”

The right-to-left orientation was dictated by the need to prevent the loss of a key molecular component, intron 2, by RNA splicing during the vector preparation. The redesigned forward-reading method crucially leaves intron 2 intact and makes the gene-translation approach less complicated, says John Tisdale, MD, chief of the Cellular and Molecular Therapeutic Branch at the National Heart, Lung, and Blood Institute, who, with Naoya Uchida, MD, PhD, came up with the idea.

In testing, the new vectors also proved longer lasting, remaining in place 4 years after transplantation.

National Institutes of Health is working to accelerate research and development through the Cure Sickle Cell Initiative, launched by NHLBI in 2018 to identify and support the most promising genetic therapies for the more than 20 million people worldwide who have sickle cell disease. NIH holds the patent for the new vector, which still will need clinical testing in humans. Clinical trials are actively enrolling.

About 100,000 people in America have sickle cell disease. Of those, an estimated 27 people have undergone experimental gene therapy using conventional vectors—virus-based vehicles for delivering “therapeutic genes.” Now National Institutes of Health researchers have taken the vector idea and revved it up, bringing the possibility of curing sickle cell disease a bit closer.

With gene therapy, doctors add a normal copy of the β-globin gene to the patient’s hematopoietic stem cells, then reinfuse the modified stem cells into the patient to produce normal disc-shaped red blood cells. In animal studies, the new vector was up to 10 times more efficient at incorporating corrective genes into bone marrow stem cells with a carrying capacity of up to 6 times greater viral load than current vectors. The new vectors also can be produced in much higher amounts, saving time and lowering costs.

The researchers call it a “forward-oriented” vector because it changes the usual direction of how gene sequences in globin-containing vectors are read: from right to left. That backward orientation—globin-containing vectors are the only therapeutic vectors in clinical development that use it—the researchers say, “has remained unchallenged for decades despite its negative impacts on efficiency.”

The right-to-left orientation was dictated by the need to prevent the loss of a key molecular component, intron 2, by RNA splicing during the vector preparation. The redesigned forward-reading method crucially leaves intron 2 intact and makes the gene-translation approach less complicated, says John Tisdale, MD, chief of the Cellular and Molecular Therapeutic Branch at the National Heart, Lung, and Blood Institute, who, with Naoya Uchida, MD, PhD, came up with the idea.

In testing, the new vectors also proved longer lasting, remaining in place 4 years after transplantation.

National Institutes of Health is working to accelerate research and development through the Cure Sickle Cell Initiative, launched by NHLBI in 2018 to identify and support the most promising genetic therapies for the more than 20 million people worldwide who have sickle cell disease. NIH holds the patent for the new vector, which still will need clinical testing in humans. Clinical trials are actively enrolling.

About 100,000 people in America have sickle cell disease. Of those, an estimated 27 people have undergone experimental gene therapy using conventional vectors—virus-based vehicles for delivering “therapeutic genes.” Now National Institutes of Health researchers have taken the vector idea and revved it up, bringing the possibility of curing sickle cell disease a bit closer.

With gene therapy, doctors add a normal copy of the β-globin gene to the patient’s hematopoietic stem cells, then reinfuse the modified stem cells into the patient to produce normal disc-shaped red blood cells. In animal studies, the new vector was up to 10 times more efficient at incorporating corrective genes into bone marrow stem cells with a carrying capacity of up to 6 times greater viral load than current vectors. The new vectors also can be produced in much higher amounts, saving time and lowering costs.

The researchers call it a “forward-oriented” vector because it changes the usual direction of how gene sequences in globin-containing vectors are read: from right to left. That backward orientation—globin-containing vectors are the only therapeutic vectors in clinical development that use it—the researchers say, “has remained unchallenged for decades despite its negative impacts on efficiency.”

The right-to-left orientation was dictated by the need to prevent the loss of a key molecular component, intron 2, by RNA splicing during the vector preparation. The redesigned forward-reading method crucially leaves intron 2 intact and makes the gene-translation approach less complicated, says John Tisdale, MD, chief of the Cellular and Molecular Therapeutic Branch at the National Heart, Lung, and Blood Institute, who, with Naoya Uchida, MD, PhD, came up with the idea.

In testing, the new vectors also proved longer lasting, remaining in place 4 years after transplantation.

National Institutes of Health is working to accelerate research and development through the Cure Sickle Cell Initiative, launched by NHLBI in 2018 to identify and support the most promising genetic therapies for the more than 20 million people worldwide who have sickle cell disease. NIH holds the patent for the new vector, which still will need clinical testing in humans. Clinical trials are actively enrolling.

People with HIV could be a safe kidney donation source for other people with HIV, according to researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and from the University of Cape Town, South Africa.

Their study followed 51 study participants with HIV who received kidney transplants from deceased donors with HIV in South Africa.

Five years after kidney transplantation, 83% of the South African cohort survived; 79% still had a functioning transplanted kidney. Those findings are similar to findings from a 2010 US NIAID-funded study, with kidneys from both living and deceased donors that reported an 88% survival rate and 74% kidney graft survival rate after 3 years.

All participants in the South African cohort were virally suppressed at the time of transplantation. The researchers did not observe any increases in viral load among those who adhered to antiretroviral therapy (ART). While 10 participants changed their ART regimens during the study, none did so because of drug resistance.

Deceased donors had strains of HIV genetically distinct from those of the transplant recipients. The investigators watched closely for signs of possible superinfections with strains of HIV that might be resistant to the recipient’s ART regimen. They identified only 1 potential case of transient superinfection, but further analyses determined that it was most likely residual virus carried over from the donor during the transplant and not a true sustained superinfection. “By using the most advanced laboratory techniques available, our team showed that HIV superinfection is of limited risk in these patients,” said study author Andrew Redd, PhD, of the NIAID Laboratory of Immunoregulation.

Such studies were illegal in the US before the HIV Organ Policy Equity (HOPE) Act passed in 2013. The law intended to increase the availability of organs for transplantation for people with HIV and permits US transplant teams with an approved research protocol to transplant organs from donors with HIV into qualified recipients with HIV and end-stage organ failure.

Two ongoing NIAID-funded clinical trials, the HOPE in Action Multicenter Kidney Study and the HOPE in Action Multicenter Liver Study, are comparing clinical outcomes among people living with HIV who receive organs from deceased donors with HIV to those who receive HIV-negative organs.

People with HIV could be a safe kidney donation source for other people with HIV, according to researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and from the University of Cape Town, South Africa.

Their study followed 51 study participants with HIV who received kidney transplants from deceased donors with HIV in South Africa.

Five years after kidney transplantation, 83% of the South African cohort survived; 79% still had a functioning transplanted kidney. Those findings are similar to findings from a 2010 US NIAID-funded study, with kidneys from both living and deceased donors that reported an 88% survival rate and 74% kidney graft survival rate after 3 years.

All participants in the South African cohort were virally suppressed at the time of transplantation. The researchers did not observe any increases in viral load among those who adhered to antiretroviral therapy (ART). While 10 participants changed their ART regimens during the study, none did so because of drug resistance.

Deceased donors had strains of HIV genetically distinct from those of the transplant recipients. The investigators watched closely for signs of possible superinfections with strains of HIV that might be resistant to the recipient’s ART regimen. They identified only 1 potential case of transient superinfection, but further analyses determined that it was most likely residual virus carried over from the donor during the transplant and not a true sustained superinfection. “By using the most advanced laboratory techniques available, our team showed that HIV superinfection is of limited risk in these patients,” said study author Andrew Redd, PhD, of the NIAID Laboratory of Immunoregulation.

Such studies were illegal in the US before the HIV Organ Policy Equity (HOPE) Act passed in 2013. The law intended to increase the availability of organs for transplantation for people with HIV and permits US transplant teams with an approved research protocol to transplant organs from donors with HIV into qualified recipients with HIV and end-stage organ failure.

Two ongoing NIAID-funded clinical trials, the HOPE in Action Multicenter Kidney Study and the HOPE in Action Multicenter Liver Study, are comparing clinical outcomes among people living with HIV who receive organs from deceased donors with HIV to those who receive HIV-negative organs.

People with HIV could be a safe kidney donation source for other people with HIV, according to researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and from the University of Cape Town, South Africa.

Their study followed 51 study participants with HIV who received kidney transplants from deceased donors with HIV in South Africa.

Five years after kidney transplantation, 83% of the South African cohort survived; 79% still had a functioning transplanted kidney. Those findings are similar to findings from a 2010 US NIAID-funded study, with kidneys from both living and deceased donors that reported an 88% survival rate and 74% kidney graft survival rate after 3 years.

All participants in the South African cohort were virally suppressed at the time of transplantation. The researchers did not observe any increases in viral load among those who adhered to antiretroviral therapy (ART). While 10 participants changed their ART regimens during the study, none did so because of drug resistance.

Deceased donors had strains of HIV genetically distinct from those of the transplant recipients. The investigators watched closely for signs of possible superinfections with strains of HIV that might be resistant to the recipient’s ART regimen. They identified only 1 potential case of transient superinfection, but further analyses determined that it was most likely residual virus carried over from the donor during the transplant and not a true sustained superinfection. “By using the most advanced laboratory techniques available, our team showed that HIV superinfection is of limited risk in these patients,” said study author Andrew Redd, PhD, of the NIAID Laboratory of Immunoregulation.

Such studies were illegal in the US before the HIV Organ Policy Equity (HOPE) Act passed in 2013. The law intended to increase the availability of organs for transplantation for people with HIV and permits US transplant teams with an approved research protocol to transplant organs from donors with HIV into qualified recipients with HIV and end-stage organ failure.

Two ongoing NIAID-funded clinical trials, the HOPE in Action Multicenter Kidney Study and the HOPE in Action Multicenter Liver Study, are comparing clinical outcomes among people living with HIV who receive organs from deceased donors with HIV to those who receive HIV-negative organs.

Mobile applications and other tech solutions that target the specific needs of patients with Alzheimer and their caregivers won the day in the first Eureka prize competition, sponsored by the National Institute on Aging.

The Improving Care for People with Alzheimer’s Disease and Related Dementias Using Technology (iCare-AD/ADRD) Challenge received 33 applications for mobile device applications or web-based methods to help users coordinate and navigate life with dementia. The judging was based on creativity and innovation, rationale and potential impact, value to relevant stakeholders, usability, and functionality and feasibility.

First place, with $250,000, went to MapHabit for mobile software that provides behavior prompts with customizable picture-and-keyword visual maps to help people with activities of daily living. The platform has different interfaces for users: people with impaired memory, caregiver, or long-term care community manager. Simple commands, such as “take a shower,” are scheduled, with feedback provided to caregivers. The system takes advantage of the brain’s habit (procedural) memory system, the researchers say, rather than the hippocampal (declarative) memory system that is damaged early in AD.

A team from University of California, Los Angeles, won second prize of $100,000 for their web-based Dementia Care Software system, which helps coordinate complex medical and social services. The software, which can be integrated into any of the leading electronic health record systems, has already been used in support of the UCLA Alzheimer’s and Dementia Care Program, a nurse-practitioner co-management approach that includes structured needs assessment, individualized dementia care plans, and round-the-clock access for assistance and advice. The researchers say more than 2,600 patients with dementia have participated in the program so far.  

Caregiver411, developed by researchers from North Carolina Agricultural and Technical State University, won the third-place prize of $50,000. The mobile app helps people make informed decisions by, for instance, capturing the care recipient’s stage of AD in order to provide targeted recommendations. Dementia caregivers can obtain tailored resources related to mental, emotional, physical, social, legal, and financial concerns. The app also gives them a forum for social connections and family chat groups through a messaging center.

The Eureka Challenge is part of the 21st Century Cures Act, signed into law in 2016, designed to help accelerate medical product development with innovations incorporating the perspectives of patients. More detailed project descriptions are available at www.nia.nih.gov/challenge-prize.

Mobile applications and other tech solutions that target the specific needs of patients with Alzheimer and their caregivers won the day in the first Eureka prize competition, sponsored by the National Institute on Aging.

The Improving Care for People with Alzheimer’s Disease and Related Dementias Using Technology (iCare-AD/ADRD) Challenge received 33 applications for mobile device applications or web-based methods to help users coordinate and navigate life with dementia. The judging was based on creativity and innovation, rationale and potential impact, value to relevant stakeholders, usability, and functionality and feasibility.

First place, with $250,000, went to MapHabit for mobile software that provides behavior prompts with customizable picture-and-keyword visual maps to help people with activities of daily living. The platform has different interfaces for users: people with impaired memory, caregiver, or long-term care community manager. Simple commands, such as “take a shower,” are scheduled, with feedback provided to caregivers. The system takes advantage of the brain’s habit (procedural) memory system, the researchers say, rather than the hippocampal (declarative) memory system that is damaged early in AD.

A team from University of California, Los Angeles, won second prize of $100,000 for their web-based Dementia Care Software system, which helps coordinate complex medical and social services. The software, which can be integrated into any of the leading electronic health record systems, has already been used in support of the UCLA Alzheimer’s and Dementia Care Program, a nurse-practitioner co-management approach that includes structured needs assessment, individualized dementia care plans, and round-the-clock access for assistance and advice. The researchers say more than 2,600 patients with dementia have participated in the program so far.  

Caregiver411, developed by researchers from North Carolina Agricultural and Technical State University, won the third-place prize of $50,000. The mobile app helps people make informed decisions by, for instance, capturing the care recipient’s stage of AD in order to provide targeted recommendations. Dementia caregivers can obtain tailored resources related to mental, emotional, physical, social, legal, and financial concerns. The app also gives them a forum for social connections and family chat groups through a messaging center.

The Eureka Challenge is part of the 21st Century Cures Act, signed into law in 2016, designed to help accelerate medical product development with innovations incorporating the perspectives of patients. More detailed project descriptions are available at www.nia.nih.gov/challenge-prize.

Mobile applications and other tech solutions that target the specific needs of patients with Alzheimer and their caregivers won the day in the first Eureka prize competition, sponsored by the National Institute on Aging.

The Improving Care for People with Alzheimer’s Disease and Related Dementias Using Technology (iCare-AD/ADRD) Challenge received 33 applications for mobile device applications or web-based methods to help users coordinate and navigate life with dementia. The judging was based on creativity and innovation, rationale and potential impact, value to relevant stakeholders, usability, and functionality and feasibility.

First place, with $250,000, went to MapHabit for mobile software that provides behavior prompts with customizable picture-and-keyword visual maps to help people with activities of daily living. The platform has different interfaces for users: people with impaired memory, caregiver, or long-term care community manager. Simple commands, such as “take a shower,” are scheduled, with feedback provided to caregivers. The system takes advantage of the brain’s habit (procedural) memory system, the researchers say, rather than the hippocampal (declarative) memory system that is damaged early in AD.

A team from University of California, Los Angeles, won second prize of $100,000 for their web-based Dementia Care Software system, which helps coordinate complex medical and social services. The software, which can be integrated into any of the leading electronic health record systems, has already been used in support of the UCLA Alzheimer’s and Dementia Care Program, a nurse-practitioner co-management approach that includes structured needs assessment, individualized dementia care plans, and round-the-clock access for assistance and advice. The researchers say more than 2,600 patients with dementia have participated in the program so far.  

Caregiver411, developed by researchers from North Carolina Agricultural and Technical State University, won the third-place prize of $50,000. The mobile app helps people make informed decisions by, for instance, capturing the care recipient’s stage of AD in order to provide targeted recommendations. Dementia caregivers can obtain tailored resources related to mental, emotional, physical, social, legal, and financial concerns. The app also gives them a forum for social connections and family chat groups through a messaging center.

The Eureka Challenge is part of the 21st Century Cures Act, signed into law in 2016, designed to help accelerate medical product development with innovations incorporating the perspectives of patients. More detailed project descriptions are available at www.nia.nih.gov/challenge-prize.

It is well established, both in research and everyday real-world experience, that posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) independently can have a huge impact on physical health. There is evidence, for instance, that both are independent “robust risk factors” for the onset of chronic physical illnesses, including musculoskeletal, digestive, and circulatory, say researchers from VA San Diego; University of California, San Diego; VA Center of Excellence for Stress and Mental Health, San Diego; National Center for PTSD, Vermont;  VA Connecticut Health Care System, and Yale. However, less is known about how the 2 conditions might synergistically affect physical health and well-being.

In this, the first population-based study of the burden of medical illness associated with PTSD, MDD, and their comorbidity, the researchers examined data from 2,732 participants in the National Health and Resilience in Veterans Study.

Of the participants, 40 had PTSD only, 141 had MDD only, and 60 had both. Among veterans who screened positive for probable PTSD, 47% also screened positive for probable MDD. Among veterans who screened positive for probable MDD, 83% screened positive for probable PTSD.

The participants with PTSD, MDD, or both had substantially greater burden of medical illness compared with that of those participants who had no lifetime history of either condition. Consistent with findings from previous studies, each group had a greater prevalence of a broad range of medical conditions, including cardiovascular, respiratory, neurologic, and chronic pain-related diseases.

However, the study results indicated that comorbid PTSD/MDD was associated with substantially greater medical comorbidity compared with either disorder alone. Veterans with co-occurring PTSD and MDD had higher odds of being diagnosed with migraine, fibromyalgia, and rheumatoid arthritis, for instance, relative to those with MDD alone.

Co-occurring PTSD/MDD was also associated with “markedly worse” cardiovascular health compared with either condition alone. Veterans with PTSD/MDD had more than twice the likelihood of being diagnosed with hypercholesterolemia and hypertension compared with those who had PTSD alone. They had more than double the odds of being diagnosed with heart disease compared with those who had only MDD.

Several factors may account for why PTSD seems to compound risk for pain-related conditions, the researchers say. People with PTSD may have increased attentional bias toward threatening internal stimuli (above and beyond MDD), which may heighten appraisal of pain; they also tend to have higher levels of anxiety sensitivity, which may amplify fear reactivity to pain. Some evidence suggests that the brain region involved in processing the affective component of pain is dysfunctional in PTSD, leading to an exaggerated response.

The associations between PTSD and pain, and PTSD/MDD and cardiovascular risks were noteworthy, the researchers say, because they were found even after “stringently controlling” for relevant covariates, including lifetime trauma exposure; combat veteran status; and alcohol, drug, and nicotine use disorder.

The finding that PTSD/MDD and PTSD were associated with higher levels of somatization is consistent with other research, the researchers note. But they say more research is needed to examine whether somatization increases vulnerability to the development of PTSD and MDD, or whether symptoms arise as a consequence of the disorders.

Further, they underscore the importance of integrating mental health services in primary care settings. Previous research has shown that older veterans tend to report mental health concerns to their primary care provider rather than seek specialty mental health treatment; they also underreport symptoms related to emotional difficulties and overreport somatic complaints.

Perhaps most important from a public health perspective, the researchers say, is that current findings suggest that veterans with co-occurring PTSD/MDD represent a “particularly high-risk group” for cardiovascular problems. The issue, they emphasize, “deserves careful attention” from the VA and other health care systems.

It is well established, both in research and everyday real-world experience, that posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) independently can have a huge impact on physical health. There is evidence, for instance, that both are independent “robust risk factors” for the onset of chronic physical illnesses, including musculoskeletal, digestive, and circulatory, say researchers from VA San Diego; University of California, San Diego; VA Center of Excellence for Stress and Mental Health, San Diego; National Center for PTSD, Vermont;  VA Connecticut Health Care System, and Yale. However, less is known about how the 2 conditions might synergistically affect physical health and well-being.

In this, the first population-based study of the burden of medical illness associated with PTSD, MDD, and their comorbidity, the researchers examined data from 2,732 participants in the National Health and Resilience in Veterans Study.

Of the participants, 40 had PTSD only, 141 had MDD only, and 60 had both. Among veterans who screened positive for probable PTSD, 47% also screened positive for probable MDD. Among veterans who screened positive for probable MDD, 83% screened positive for probable PTSD.

The participants with PTSD, MDD, or both had substantially greater burden of medical illness compared with that of those participants who had no lifetime history of either condition. Consistent with findings from previous studies, each group had a greater prevalence of a broad range of medical conditions, including cardiovascular, respiratory, neurologic, and chronic pain-related diseases.

However, the study results indicated that comorbid PTSD/MDD was associated with substantially greater medical comorbidity compared with either disorder alone. Veterans with co-occurring PTSD and MDD had higher odds of being diagnosed with migraine, fibromyalgia, and rheumatoid arthritis, for instance, relative to those with MDD alone.

Co-occurring PTSD/MDD was also associated with “markedly worse” cardiovascular health compared with either condition alone. Veterans with PTSD/MDD had more than twice the likelihood of being diagnosed with hypercholesterolemia and hypertension compared with those who had PTSD alone. They had more than double the odds of being diagnosed with heart disease compared with those who had only MDD.

Several factors may account for why PTSD seems to compound risk for pain-related conditions, the researchers say. People with PTSD may have increased attentional bias toward threatening internal stimuli (above and beyond MDD), which may heighten appraisal of pain; they also tend to have higher levels of anxiety sensitivity, which may amplify fear reactivity to pain. Some evidence suggests that the brain region involved in processing the affective component of pain is dysfunctional in PTSD, leading to an exaggerated response.

The associations between PTSD and pain, and PTSD/MDD and cardiovascular risks were noteworthy, the researchers say, because they were found even after “stringently controlling” for relevant covariates, including lifetime trauma exposure; combat veteran status; and alcohol, drug, and nicotine use disorder.

The finding that PTSD/MDD and PTSD were associated with higher levels of somatization is consistent with other research, the researchers note. But they say more research is needed to examine whether somatization increases vulnerability to the development of PTSD and MDD, or whether symptoms arise as a consequence of the disorders.

Further, they underscore the importance of integrating mental health services in primary care settings. Previous research has shown that older veterans tend to report mental health concerns to their primary care provider rather than seek specialty mental health treatment; they also underreport symptoms related to emotional difficulties and overreport somatic complaints.

Perhaps most important from a public health perspective, the researchers say, is that current findings suggest that veterans with co-occurring PTSD/MDD represent a “particularly high-risk group” for cardiovascular problems. The issue, they emphasize, “deserves careful attention” from the VA and other health care systems.

It is well established, both in research and everyday real-world experience, that posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) independently can have a huge impact on physical health. There is evidence, for instance, that both are independent “robust risk factors” for the onset of chronic physical illnesses, including musculoskeletal, digestive, and circulatory, say researchers from VA San Diego; University of California, San Diego; VA Center of Excellence for Stress and Mental Health, San Diego; National Center for PTSD, Vermont;  VA Connecticut Health Care System, and Yale. However, less is known about how the 2 conditions might synergistically affect physical health and well-being.

In this, the first population-based study of the burden of medical illness associated with PTSD, MDD, and their comorbidity, the researchers examined data from 2,732 participants in the National Health and Resilience in Veterans Study.

Of the participants, 40 had PTSD only, 141 had MDD only, and 60 had both. Among veterans who screened positive for probable PTSD, 47% also screened positive for probable MDD. Among veterans who screened positive for probable MDD, 83% screened positive for probable PTSD.

The participants with PTSD, MDD, or both had substantially greater burden of medical illness compared with that of those participants who had no lifetime history of either condition. Consistent with findings from previous studies, each group had a greater prevalence of a broad range of medical conditions, including cardiovascular, respiratory, neurologic, and chronic pain-related diseases.

However, the study results indicated that comorbid PTSD/MDD was associated with substantially greater medical comorbidity compared with either disorder alone. Veterans with co-occurring PTSD and MDD had higher odds of being diagnosed with migraine, fibromyalgia, and rheumatoid arthritis, for instance, relative to those with MDD alone.

Co-occurring PTSD/MDD was also associated with “markedly worse” cardiovascular health compared with either condition alone. Veterans with PTSD/MDD had more than twice the likelihood of being diagnosed with hypercholesterolemia and hypertension compared with those who had PTSD alone. They had more than double the odds of being diagnosed with heart disease compared with those who had only MDD.

Several factors may account for why PTSD seems to compound risk for pain-related conditions, the researchers say. People with PTSD may have increased attentional bias toward threatening internal stimuli (above and beyond MDD), which may heighten appraisal of pain; they also tend to have higher levels of anxiety sensitivity, which may amplify fear reactivity to pain. Some evidence suggests that the brain region involved in processing the affective component of pain is dysfunctional in PTSD, leading to an exaggerated response.

The associations between PTSD and pain, and PTSD/MDD and cardiovascular risks were noteworthy, the researchers say, because they were found even after “stringently controlling” for relevant covariates, including lifetime trauma exposure; combat veteran status; and alcohol, drug, and nicotine use disorder.

The finding that PTSD/MDD and PTSD were associated with higher levels of somatization is consistent with other research, the researchers note. But they say more research is needed to examine whether somatization increases vulnerability to the development of PTSD and MDD, or whether symptoms arise as a consequence of the disorders.

Further, they underscore the importance of integrating mental health services in primary care settings. Previous research has shown that older veterans tend to report mental health concerns to their primary care provider rather than seek specialty mental health treatment; they also underreport symptoms related to emotional difficulties and overreport somatic complaints.

Perhaps most important from a public health perspective, the researchers say, is that current findings suggest that veterans with co-occurring PTSD/MDD represent a “particularly high-risk group” for cardiovascular problems. The issue, they emphasize, “deserves careful attention” from the VA and other health care systems.

Working memory (WM)—the function that allows us to temporarily store information and use it for cognitive tasks like learning, reasoning, and comprehension—is thought to play an important role in managing anxiety and intrusive symptoms of posttraumatic stress disorder (PTSD). Researchers have found inefficient filtering of threatening material from WM and increased storage of task-irrelevant threat distractors are associated with elevated anxiety. Thus, veterans with high levels of anxiety may disproportionately allocate cognitive resources toward threatening stimuli, and have trouble keeping threatening thoughts from entering WM and staying there. People with PTSD also have been shown to have problems using WM in emotional contexts, making it hard for them to deal with stressful situations in work and personal life. Some research has suggested that WM training that incorporates affective stimuli may increase the ability to use WM in emotional contexts. In a pilot study, researchers from Medical College of Wisconsin and University of Wisconsin-Milwaukee expanded on that possibility by testing 2 kinds of WM training in 21 veterans with elevated PTSD symptoms.

Participants completed a pretest, 15 sessions of at-home computerized training, a posttest, and a 1-month follow-up session. The computerized tests included tasks to measure WM capacity, such as solving math questions while trying to remember a set of unrelated numbers. The participants were then assigned to active emotional WM training (n-back) or control emotional WM training (1-back). The n-back training involved constant updating of information stored in WM and shifting between visual and auditory stimuli using 8 different faces and 8 different negative words. The training sessions started at the 1-back level and increased in difficulty level by level with performance with > 95% accuracy, or were scaled back with performance with < 75% accuracy. The control training was the same but consisted only of 1 level.

Overall, the researchers say, contrary to their hypothesis, they did not find a significant difference in results from the 2 groups. But they did find that both trainings had an overall “significant and sizable” impact on PTSD symptoms in both groups: 73% of the n-back group and 60% of the 1-back group had a reduction of ≥ 10 points on the PTSD Checklist total scores, which the researchers say is considered a clinically meaningful change. Moreover, both groups showed a clinically meaningful reduction in symptoms at follow-up: 55% and 40%, respectively.

It was interesting, the researchers say, that both groups showed improvement, especially with the 1-back intervention, which they had used as a “minimally effective” control condition. They also note that, anecdotally, the participants found both interventions “quite challenging.” It may be that in this population even the 1-back intervention is enough to detectably reduce symptoms, the researchers say. They were also encouraged to see that the n-back condition (marginally) outperformed the 1-back condition in improving reexperiencing symptoms, theoretically the most relevant training target of WM-focused intervention. The researchers  believe that their study yields useful pilot data, suggesting that n-back training can have a clinical impact primarily by reducing reexperiencing symptoms, which are highly likely to indicate the presence of impaired WM functioning.

Working memory (WM)—the function that allows us to temporarily store information and use it for cognitive tasks like learning, reasoning, and comprehension—is thought to play an important role in managing anxiety and intrusive symptoms of posttraumatic stress disorder (PTSD). Researchers have found inefficient filtering of threatening material from WM and increased storage of task-irrelevant threat distractors are associated with elevated anxiety. Thus, veterans with high levels of anxiety may disproportionately allocate cognitive resources toward threatening stimuli, and have trouble keeping threatening thoughts from entering WM and staying there. People with PTSD also have been shown to have problems using WM in emotional contexts, making it hard for them to deal with stressful situations in work and personal life. Some research has suggested that WM training that incorporates affective stimuli may increase the ability to use WM in emotional contexts. In a pilot study, researchers from Medical College of Wisconsin and University of Wisconsin-Milwaukee expanded on that possibility by testing 2 kinds of WM training in 21 veterans with elevated PTSD symptoms.

Participants completed a pretest, 15 sessions of at-home computerized training, a posttest, and a 1-month follow-up session. The computerized tests included tasks to measure WM capacity, such as solving math questions while trying to remember a set of unrelated numbers. The participants were then assigned to active emotional WM training (n-back) or control emotional WM training (1-back). The n-back training involved constant updating of information stored in WM and shifting between visual and auditory stimuli using 8 different faces and 8 different negative words. The training sessions started at the 1-back level and increased in difficulty level by level with performance with > 95% accuracy, or were scaled back with performance with < 75% accuracy. The control training was the same but consisted only of 1 level.

Overall, the researchers say, contrary to their hypothesis, they did not find a significant difference in results from the 2 groups. But they did find that both trainings had an overall “significant and sizable” impact on PTSD symptoms in both groups: 73% of the n-back group and 60% of the 1-back group had a reduction of ≥ 10 points on the PTSD Checklist total scores, which the researchers say is considered a clinically meaningful change. Moreover, both groups showed a clinically meaningful reduction in symptoms at follow-up: 55% and 40%, respectively.

It was interesting, the researchers say, that both groups showed improvement, especially with the 1-back intervention, which they had used as a “minimally effective” control condition. They also note that, anecdotally, the participants found both interventions “quite challenging.” It may be that in this population even the 1-back intervention is enough to detectably reduce symptoms, the researchers say. They were also encouraged to see that the n-back condition (marginally) outperformed the 1-back condition in improving reexperiencing symptoms, theoretically the most relevant training target of WM-focused intervention. The researchers  believe that their study yields useful pilot data, suggesting that n-back training can have a clinical impact primarily by reducing reexperiencing symptoms, which are highly likely to indicate the presence of impaired WM functioning.

Working memory (WM)—the function that allows us to temporarily store information and use it for cognitive tasks like learning, reasoning, and comprehension—is thought to play an important role in managing anxiety and intrusive symptoms of posttraumatic stress disorder (PTSD). Researchers have found inefficient filtering of threatening material from WM and increased storage of task-irrelevant threat distractors are associated with elevated anxiety. Thus, veterans with high levels of anxiety may disproportionately allocate cognitive resources toward threatening stimuli, and have trouble keeping threatening thoughts from entering WM and staying there. People with PTSD also have been shown to have problems using WM in emotional contexts, making it hard for them to deal with stressful situations in work and personal life. Some research has suggested that WM training that incorporates affective stimuli may increase the ability to use WM in emotional contexts. In a pilot study, researchers from Medical College of Wisconsin and University of Wisconsin-Milwaukee expanded on that possibility by testing 2 kinds of WM training in 21 veterans with elevated PTSD symptoms.

Participants completed a pretest, 15 sessions of at-home computerized training, a posttest, and a 1-month follow-up session. The computerized tests included tasks to measure WM capacity, such as solving math questions while trying to remember a set of unrelated numbers. The participants were then assigned to active emotional WM training (n-back) or control emotional WM training (1-back). The n-back training involved constant updating of information stored in WM and shifting between visual and auditory stimuli using 8 different faces and 8 different negative words. The training sessions started at the 1-back level and increased in difficulty level by level with performance with > 95% accuracy, or were scaled back with performance with < 75% accuracy. The control training was the same but consisted only of 1 level.

Overall, the researchers say, contrary to their hypothesis, they did not find a significant difference in results from the 2 groups. But they did find that both trainings had an overall “significant and sizable” impact on PTSD symptoms in both groups: 73% of the n-back group and 60% of the 1-back group had a reduction of ≥ 10 points on the PTSD Checklist total scores, which the researchers say is considered a clinically meaningful change. Moreover, both groups showed a clinically meaningful reduction in symptoms at follow-up: 55% and 40%, respectively.

It was interesting, the researchers say, that both groups showed improvement, especially with the 1-back intervention, which they had used as a “minimally effective” control condition. They also note that, anecdotally, the participants found both interventions “quite challenging.” It may be that in this population even the 1-back intervention is enough to detectably reduce symptoms, the researchers say. They were also encouraged to see that the n-back condition (marginally) outperformed the 1-back condition in improving reexperiencing symptoms, theoretically the most relevant training target of WM-focused intervention. The researchers  believe that their study yields useful pilot data, suggesting that n-back training can have a clinical impact primarily by reducing reexperiencing symptoms, which are highly likely to indicate the presence of impaired WM functioning.

Why do we forget some dreams and remember others? Researchers in a study funded by the National Institute of Neurological Disorders and Stroke say our dream memory may be controlled by a group of neurons commonly associated with appetite. Their findings could shed light on a wide range of memory-related conditions, including posttraumatic stress disorder (PTSD) and Alzheimer disease.

Studies have already shown that sleep helps the brain store new memories and eliminate excess information. Recent mouse studies have found that during sleep the brain prunes synaptic connections made between neurons involved in some types of learning.

But this study shows how that might happen.

The researchers have previously demonstrated that narcolepsy might be linked to the loss of hypocretin/orexin-making neurons in the hypothalamus. In this study, they looked at neighboring cells that produce melanin-concentrating hormone (MCH), which is involved in the control of both sleep and appetite. A majority (53%) of hypothalamic MCH cells fired in mice during REM sleep; 35% fired when they were awake, and 12% fired at both times.

Those cells also may play a role in learning and memory, the researchers suggest. To test their theory that MCH cells might help the brain store memories, they used “genetic tools” to turn MCH neurons on and off during memory tests.

Surprisingly, the researchers say, pharmacogenetic activation—turning on the MCH cells—worsened memory; genetic ablation—turning them off—improved memory. Further experiments suggested MCH neurons exclusively played this role during REM sleep.

The results suggest that MCH neurons help the brain actively forget new, possibly unimportant information. “Since dreams are thought to primarily occur during REM sleep,” says Thomas Kilduff, PhD, senior author of the study, “the sleep stage when the MCH cells turn on, activation of these cells may prevent the content of a dream from being stored in the hippocampus—consequently, the dream is quickly forgotten.”

Why do we forget some dreams and remember others? Researchers in a study funded by the National Institute of Neurological Disorders and Stroke say our dream memory may be controlled by a group of neurons commonly associated with appetite. Their findings could shed light on a wide range of memory-related conditions, including posttraumatic stress disorder (PTSD) and Alzheimer disease.

Studies have already shown that sleep helps the brain store new memories and eliminate excess information. Recent mouse studies have found that during sleep the brain prunes synaptic connections made between neurons involved in some types of learning.

But this study shows how that might happen.

The researchers have previously demonstrated that narcolepsy might be linked to the loss of hypocretin/orexin-making neurons in the hypothalamus. In this study, they looked at neighboring cells that produce melanin-concentrating hormone (MCH), which is involved in the control of both sleep and appetite. A majority (53%) of hypothalamic MCH cells fired in mice during REM sleep; 35% fired when they were awake, and 12% fired at both times.

Those cells also may play a role in learning and memory, the researchers suggest. To test their theory that MCH cells might help the brain store memories, they used “genetic tools” to turn MCH neurons on and off during memory tests.

Surprisingly, the researchers say, pharmacogenetic activation—turning on the MCH cells—worsened memory; genetic ablation—turning them off—improved memory. Further experiments suggested MCH neurons exclusively played this role during REM sleep.

The results suggest that MCH neurons help the brain actively forget new, possibly unimportant information. “Since dreams are thought to primarily occur during REM sleep,” says Thomas Kilduff, PhD, senior author of the study, “the sleep stage when the MCH cells turn on, activation of these cells may prevent the content of a dream from being stored in the hippocampus—consequently, the dream is quickly forgotten.”

Why do we forget some dreams and remember others? Researchers in a study funded by the National Institute of Neurological Disorders and Stroke say our dream memory may be controlled by a group of neurons commonly associated with appetite. Their findings could shed light on a wide range of memory-related conditions, including posttraumatic stress disorder (PTSD) and Alzheimer disease.

Studies have already shown that sleep helps the brain store new memories and eliminate excess information. Recent mouse studies have found that during sleep the brain prunes synaptic connections made between neurons involved in some types of learning.

But this study shows how that might happen.

The researchers have previously demonstrated that narcolepsy might be linked to the loss of hypocretin/orexin-making neurons in the hypothalamus. In this study, they looked at neighboring cells that produce melanin-concentrating hormone (MCH), which is involved in the control of both sleep and appetite. A majority (53%) of hypothalamic MCH cells fired in mice during REM sleep; 35% fired when they were awake, and 12% fired at both times.

Those cells also may play a role in learning and memory, the researchers suggest. To test their theory that MCH cells might help the brain store memories, they used “genetic tools” to turn MCH neurons on and off during memory tests.

Surprisingly, the researchers say, pharmacogenetic activation—turning on the MCH cells—worsened memory; genetic ablation—turning them off—improved memory. Further experiments suggested MCH neurons exclusively played this role during REM sleep.

The results suggest that MCH neurons help the brain actively forget new, possibly unimportant information. “Since dreams are thought to primarily occur during REM sleep,” says Thomas Kilduff, PhD, senior author of the study, “the sleep stage when the MCH cells turn on, activation of these cells may prevent the content of a dream from being stored in the hippocampus—consequently, the dream is quickly forgotten.”

Even a mild blast to the brain can cause long-term, life-changing health problems, says Riyi Shi, professor of neuroscience and biomedical engineering at Purdue University in Lafayette, Indiana. However, the effects can be subtle: “The individual appears to be fine, and it’s difficult to tell if you just look at a person. But the fact is that these types of hits are multiplied over years and often ignored until someone reaches an age when other factors come into play.”

Treating the incidents sooner can help mitigate later-life issues, such as Parkinson disease (PD). Shi led a study that found checking the urine within 7 days following a blast incident—even a mild one—provides faster diagnosis when brain injury is suspected.

A simple urine analysis reveals elevations in the neurotoxin acrolein, Shi says, which is a biomarker for brain injury. In the study, the researchers evaluated the changes of α-synuclein and tyrosine hydroxylase, hallmarks of PD, and acrolein, a marker of oxidative stress. The researchers say in animal models of PD and traumatic brain injury (TBI), acrolein is “likely a point of pathogenic convergence.”

They found that after a single mild blast TBI, acrolein was elevated for up to a week, systemically in urine, and in whole brain tissue, specifically the substantia nigra and striatum. The elevation was accompanied by heightened α-synuclein oligomerization, dopaminergic dysregulation, and acrolein/α-synuclein interaction in the same brain regions. Taken together, the researchers say, the data suggest that acrolein likely plays a key role in inducing PD following blast TBI.

The presence of the biomarker “alerts us to the injury, creating an opportunity for intervention,” Shi says. “This early detection and subsequent treatment window could offer tremendous benefits for long-term patient neurologic health.”

Even a mild blast to the brain can cause long-term, life-changing health problems, says Riyi Shi, professor of neuroscience and biomedical engineering at Purdue University in Lafayette, Indiana. However, the effects can be subtle: “The individual appears to be fine, and it’s difficult to tell if you just look at a person. But the fact is that these types of hits are multiplied over years and often ignored until someone reaches an age when other factors come into play.”

Treating the incidents sooner can help mitigate later-life issues, such as Parkinson disease (PD). Shi led a study that found checking the urine within 7 days following a blast incident—even a mild one—provides faster diagnosis when brain injury is suspected.

A simple urine analysis reveals elevations in the neurotoxin acrolein, Shi says, which is a biomarker for brain injury. In the study, the researchers evaluated the changes of α-synuclein and tyrosine hydroxylase, hallmarks of PD, and acrolein, a marker of oxidative stress. The researchers say in animal models of PD and traumatic brain injury (TBI), acrolein is “likely a point of pathogenic convergence.”

They found that after a single mild blast TBI, acrolein was elevated for up to a week, systemically in urine, and in whole brain tissue, specifically the substantia nigra and striatum. The elevation was accompanied by heightened α-synuclein oligomerization, dopaminergic dysregulation, and acrolein/α-synuclein interaction in the same brain regions. Taken together, the researchers say, the data suggest that acrolein likely plays a key role in inducing PD following blast TBI.

The presence of the biomarker “alerts us to the injury, creating an opportunity for intervention,” Shi says. “This early detection and subsequent treatment window could offer tremendous benefits for long-term patient neurologic health.”

Even a mild blast to the brain can cause long-term, life-changing health problems, says Riyi Shi, professor of neuroscience and biomedical engineering at Purdue University in Lafayette, Indiana. However, the effects can be subtle: “The individual appears to be fine, and it’s difficult to tell if you just look at a person. But the fact is that these types of hits are multiplied over years and often ignored until someone reaches an age when other factors come into play.”

Treating the incidents sooner can help mitigate later-life issues, such as Parkinson disease (PD). Shi led a study that found checking the urine within 7 days following a blast incident—even a mild one—provides faster diagnosis when brain injury is suspected.

A simple urine analysis reveals elevations in the neurotoxin acrolein, Shi says, which is a biomarker for brain injury. In the study, the researchers evaluated the changes of α-synuclein and tyrosine hydroxylase, hallmarks of PD, and acrolein, a marker of oxidative stress. The researchers say in animal models of PD and traumatic brain injury (TBI), acrolein is “likely a point of pathogenic convergence.”

They found that after a single mild blast TBI, acrolein was elevated for up to a week, systemically in urine, and in whole brain tissue, specifically the substantia nigra and striatum. The elevation was accompanied by heightened α-synuclein oligomerization, dopaminergic dysregulation, and acrolein/α-synuclein interaction in the same brain regions. Taken together, the researchers say, the data suggest that acrolein likely plays a key role in inducing PD following blast TBI.

The presence of the biomarker “alerts us to the injury, creating an opportunity for intervention,” Shi says. “This early detection and subsequent treatment window could offer tremendous benefits for long-term patient neurologic health.”

Stanley Patrick Weber, a former Indian Health Service (IHS) pediatrician, was convicted September 27 on 8 counts of sexual abuse of 4 Native American boys under his care at the Pine Ridge Indian Reservation, Oglala Lakota County, South Dakota.

Weber was an employee of the IHS from 1986 until he resigned in 2016. During that time, although suspicions were rampant that he was abusing young patients, he was moved from one reservation to another. An investigation by The Wall Street Journal and PBS/Frontline found officials in the IHS chain of command “ignored warning signs” and tried to silence whistleblowers.

Weber also was convicted last year and served time for abusing 2 boys at another government hospital in Montana before he arrived at Pine Ridge.

The Pine Ridge Reservation is home to some of the poorest communities in the US, with a dropout rate of > 70%, and a teen suicide rate 150% higher than America’s as a whole. Many of the youths testifying in the case described difficult childhoods, according to the Frontline program. In addition to assaulting them during health care visits, Weber lured them to his home with offers of alcohol and cash.

A White House task force was created to address the agency’s failures. In a statement, Rear Adm Michael Weahkee, IHS principal deputy director, said the IHS is “doing all we can throughout our agency to strengthen our protection for patients.” Steps taken include reinforcing with staff the prohibitions against inappropriate contact with children, reminding staff of the protections for whistleblowers, and hiring Integritas Creative Solutions to conduct a medical quality assurance review to examine whether laws, policies and procedures have been followed with regard to protecting patients from sexual abuse. The review complements work done by the Presidential Task Force on Protecting Native American Children in the Indian Health Service System and a separate review by the HHS Office of the Inspector General.

The IHS also is providing professional counseling for victims. Services do not have to be at an IHS facility or with an IHS provider. A confidential hot line has been established at 301-443-0658.

Weahkee calls the verdict “a long-awaited victory.” But, he adds, “we know that it will not completely heal the wounds inflicted on Dr. Weber’s victims.”

Stanley Patrick Weber, a former Indian Health Service (IHS) pediatrician, was convicted September 27 on 8 counts of sexual abuse of 4 Native American boys under his care at the Pine Ridge Indian Reservation, Oglala Lakota County, South Dakota.

Weber was an employee of the IHS from 1986 until he resigned in 2016. During that time, although suspicions were rampant that he was abusing young patients, he was moved from one reservation to another. An investigation by The Wall Street Journal and PBS/Frontline found officials in the IHS chain of command “ignored warning signs” and tried to silence whistleblowers.

Weber also was convicted last year and served time for abusing 2 boys at another government hospital in Montana before he arrived at Pine Ridge.

The Pine Ridge Reservation is home to some of the poorest communities in the US, with a dropout rate of > 70%, and a teen suicide rate 150% higher than America’s as a whole. Many of the youths testifying in the case described difficult childhoods, according to the Frontline program. In addition to assaulting them during health care visits, Weber lured them to his home with offers of alcohol and cash.

A White House task force was created to address the agency’s failures. In a statement, Rear Adm Michael Weahkee, IHS principal deputy director, said the IHS is “doing all we can throughout our agency to strengthen our protection for patients.” Steps taken include reinforcing with staff the prohibitions against inappropriate contact with children, reminding staff of the protections for whistleblowers, and hiring Integritas Creative Solutions to conduct a medical quality assurance review to examine whether laws, policies and procedures have been followed with regard to protecting patients from sexual abuse. The review complements work done by the Presidential Task Force on Protecting Native American Children in the Indian Health Service System and a separate review by the HHS Office of the Inspector General.

The IHS also is providing professional counseling for victims. Services do not have to be at an IHS facility or with an IHS provider. A confidential hot line has been established at 301-443-0658.

Weahkee calls the verdict “a long-awaited victory.” But, he adds, “we know that it will not completely heal the wounds inflicted on Dr. Weber’s victims.”

Stanley Patrick Weber, a former Indian Health Service (IHS) pediatrician, was convicted September 27 on 8 counts of sexual abuse of 4 Native American boys under his care at the Pine Ridge Indian Reservation, Oglala Lakota County, South Dakota.

Weber was an employee of the IHS from 1986 until he resigned in 2016. During that time, although suspicions were rampant that he was abusing young patients, he was moved from one reservation to another. An investigation by The Wall Street Journal and PBS/Frontline found officials in the IHS chain of command “ignored warning signs” and tried to silence whistleblowers.

Weber also was convicted last year and served time for abusing 2 boys at another government hospital in Montana before he arrived at Pine Ridge.

The Pine Ridge Reservation is home to some of the poorest communities in the US, with a dropout rate of > 70%, and a teen suicide rate 150% higher than America’s as a whole. Many of the youths testifying in the case described difficult childhoods, according to the Frontline program. In addition to assaulting them during health care visits, Weber lured them to his home with offers of alcohol and cash.

A White House task force was created to address the agency’s failures. In a statement, Rear Adm Michael Weahkee, IHS principal deputy director, said the IHS is “doing all we can throughout our agency to strengthen our protection for patients.” Steps taken include reinforcing with staff the prohibitions against inappropriate contact with children, reminding staff of the protections for whistleblowers, and hiring Integritas Creative Solutions to conduct a medical quality assurance review to examine whether laws, policies and procedures have been followed with regard to protecting patients from sexual abuse. The review complements work done by the Presidential Task Force on Protecting Native American Children in the Indian Health Service System and a separate review by the HHS Office of the Inspector General.

The IHS also is providing professional counseling for victims. Services do not have to be at an IHS facility or with an IHS provider. A confidential hot line has been established at 301-443-0658.

Weahkee calls the verdict “a long-awaited victory.” But, he adds, “we know that it will not completely heal the wounds inflicted on Dr. Weber’s victims.”

When first responders arrive at a scene where illicit drugs may be present, they could be at risk of dangerous exposure. They might inhale drugs; they can have contact through mucous membranes or through needlesticks.

A major concern is exposure to fentanyl or its analogues, which can lead to symptoms, including rapid onset of life-threatening respiratory depression. The exception is skin contact, which is not expected to have toxic effects if the visible contamination is removed promptly.

To help EMS providers and other responders protect themselves, the National Institute for Occupational Safety and Health (NIOSH) has released a new virtual toolkit with videos, infographics, and postcards based on NIOSH safety recommendations.

The resources highlight how best to assess the scene for hazards that may indicate the presence of illicit drugs and what to do—for example, use soap and water, not hand sanitizer (it doesn’t remove illicit drugs and may increase exposure), and don’t eat, drink, smoke, or use the bathroom in the affected area. The infographics also show how to decontaminate and prevent “take-home exposure” to protect responders’ families. The guidelines extend to procedures for protecting working dogs exposed to the drugs.

NIOSH notes that it has no occupational exposure data on fentanyl or its analogues for emergency responders. The recommendations are based on the reported toxicity and the chemical and physical properties of fentanyl and its analogues, NIOSH guidance for similar chemicals, recommendations from previous NIOSH health hazard evaluation reports, and “the basic principles of industrial hygiene.” As new research becomes available, NIOSH says, the recommendations will be updated.

The toolkit resources are shareable and available for disseminating via print, social media, text, and more. The kit is accessible at https://www.cdc.gov/niosh/topics/fentanyl/toolkit.html.

When first responders arrive at a scene where illicit drugs may be present, they could be at risk of dangerous exposure. They might inhale drugs; they can have contact through mucous membranes or through needlesticks.

A major concern is exposure to fentanyl or its analogues, which can lead to symptoms, including rapid onset of life-threatening respiratory depression. The exception is skin contact, which is not expected to have toxic effects if the visible contamination is removed promptly.

To help EMS providers and other responders protect themselves, the National Institute for Occupational Safety and Health (NIOSH) has released a new virtual toolkit with videos, infographics, and postcards based on NIOSH safety recommendations.

The resources highlight how best to assess the scene for hazards that may indicate the presence of illicit drugs and what to do—for example, use soap and water, not hand sanitizer (it doesn’t remove illicit drugs and may increase exposure), and don’t eat, drink, smoke, or use the bathroom in the affected area. The infographics also show how to decontaminate and prevent “take-home exposure” to protect responders’ families. The guidelines extend to procedures for protecting working dogs exposed to the drugs.

NIOSH notes that it has no occupational exposure data on fentanyl or its analogues for emergency responders. The recommendations are based on the reported toxicity and the chemical and physical properties of fentanyl and its analogues, NIOSH guidance for similar chemicals, recommendations from previous NIOSH health hazard evaluation reports, and “the basic principles of industrial hygiene.” As new research becomes available, NIOSH says, the recommendations will be updated.

The toolkit resources are shareable and available for disseminating via print, social media, text, and more. The kit is accessible at https://www.cdc.gov/niosh/topics/fentanyl/toolkit.html.

When first responders arrive at a scene where illicit drugs may be present, they could be at risk of dangerous exposure. They might inhale drugs; they can have contact through mucous membranes or through needlesticks.

A major concern is exposure to fentanyl or its analogues, which can lead to symptoms, including rapid onset of life-threatening respiratory depression. The exception is skin contact, which is not expected to have toxic effects if the visible contamination is removed promptly.

To help EMS providers and other responders protect themselves, the National Institute for Occupational Safety and Health (NIOSH) has released a new virtual toolkit with videos, infographics, and postcards based on NIOSH safety recommendations.

The resources highlight how best to assess the scene for hazards that may indicate the presence of illicit drugs and what to do—for example, use soap and water, not hand sanitizer (it doesn’t remove illicit drugs and may increase exposure), and don’t eat, drink, smoke, or use the bathroom in the affected area. The infographics also show how to decontaminate and prevent “take-home exposure” to protect responders’ families. The guidelines extend to procedures for protecting working dogs exposed to the drugs.

NIOSH notes that it has no occupational exposure data on fentanyl or its analogues for emergency responders. The recommendations are based on the reported toxicity and the chemical and physical properties of fentanyl and its analogues, NIOSH guidance for similar chemicals, recommendations from previous NIOSH health hazard evaluation reports, and “the basic principles of industrial hygiene.” As new research becomes available, NIOSH says, the recommendations will be updated.

The toolkit resources are shareable and available for disseminating via print, social media, text, and more. The kit is accessible at https://www.cdc.gov/niosh/topics/fentanyl/toolkit.html.